We are live on ! Find out more
KZIA

Kazia Therapeutics
KZIA

7 hedge funds and large institutions have $278K invested in Kazia Therapeutics in 2017 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0% more funds holding

Funds holding: 7 → 7 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

29% less capital invested

Capital invested by funds: $394K → $278K (-$116K)

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$16.8K
2
Citadel Advisors
Citadel Advisors
Florida
+$4.91K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$6.61K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$131K +$16.8K +89 +14%
Renaissance Technologies
2
Renaissance Technologies
New York
$124K – – –
Citadel Advisors
3
Citadel Advisors
Florida
$16K +$4.91K +26 +41%
Royal Bank of Canada
4
Royal Bank of Canada
Ontario, Canada
$5K – – –
UBS Group
5
UBS Group
Switzerland
$2K -$6.61K -35 -78%

KZIA Hedge Fund Activity: Q2 2017 in Review

7 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q2 2017, worth a combined $278K — down 29% from $394K a quarter earlier.

Fund positioning in KZIA was balanced in Q2 2017: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $16.8K. The largest seller was UBS Group, cutting an estimated $6.61K.

  • 7 institutional investors held Kazia Therapeutics (KZIA) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $278K of Kazia Therapeutics stock for Q2 2017, down 29% quarter-over-quarter.
  • 0 funds opened new Kazia Therapeutics positions in Q2 2017 and 0 closed out.
  • The largest Kazia Therapeutics buyer in Q2 2017 was Morgan Stanley, an estimated $16.8K added.
  • The largest Kazia Therapeutics seller in Q2 2017 was UBS Group, an estimated $6.61K sold.

Based on aggregated 13F filings for Q2 2017.